Arne Scheu

Company: Valink Therapeutics

Job title: Co-Founder & Chief Executive Officer

Seminars:

Increasing Tissue Penetration & Limiting Immunogenicity: Differentiating Through Novel Conjugate Design 2:10 pm

Targeting proteins expressed in a larger number of cancers versus receptors predominantly expressed in solid tumor subsets Increasing tissue penetration propensity to achieve more significant internalization and intracellular exposure to the payload with smaller proteins  Leveraging reduced screening cycles required to optimize linker chemistry with smaller proteins, and modulatory to conjugate different payload typesRead more

day: Conference Day Two